biotech updates 05/02:

$akao -29% adcom
$espr -35% safety trial concerns
$nvs biosimilar rituximab crl
+pipeline updates for $blue $cnat $drrx $exel $vnda $achn $amrn $bpmc $espr $mrns $ $zlab
https://t.co/oi8lcnebg6